NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status (Descending) |
---|---|---|---|---|---|---|---|---|---|---|---|
72603-0101-01 | 72603-0101 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 17, 2019 | In Use | |
72603-0301-01 | 72603-0301 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 17, 2019 | In Use | |
69539-0158-01 | 69539-0158 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
69539-0159-01 | 69539-0159 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
69539-0157-01 | 69539-0157 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 26, 2020 | In Use | |
70255-0025-01 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | June 27, 2018 | In Use | |
70255-0025-03 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | June 27, 2018 | In Use | |
70255-0025-05 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug. 3, 2020 | In Use | |
70255-0025-06 | 70255-0025 | Encorafenib | BRAFTOVI | 75.0 mg/1 | Chemotherapy | BRAF Inhibitor | V600E | Oral | Aug. 3, 2020 | In Use | |
42806-0359-25 | 42806-0359 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | April 16, 2020 | In Use |
Found 10,000 results in 12 milliseconds — Export these results